APCDD1 inhibitors are a chemical class specifically designed to target the Adenomatosis Polyposis Coli Down-regulated 1 (APCDD1) protein. This protein is known to play a crucial role in various biological processes, including the regulation of Wnt signaling pathways, which are pivotal in cellular communication and developmental stages. The inhibitors in this class work by binding to APCDD1, effectively modulating its activity. This modulation can lead to the alteration of the Wnt/β-catenin pathway, a pathway known for its role in cell proliferation, differentiation, and apoptosis. The specific binding affinity of APCDD1 inhibitors ensures that they effectively target and inhibit the function of APCDD1, which has ramifications on the downstream signaling processes. This targeted inhibition is achieved through a variety of molecular mechanisms, such as competitive inhibition, where the inhibitor molecule competes with natural ligands or substrates for binding sites on APCDD1, or allosteric inhibition, where the inhibitor binds to a different site on the protein, inducing a conformational change that reduces its activity.
APCDD1 inhibitors are diverse, comprising a range of small molecules with distinct chemical structures and properties. This diversity allows for the specific tuning of their pharmacokinetic and pharmacodynamic profiles to optimize their interaction with APCDD1. The design of these inhibitors often involves the utilization of structure-activity relationship (SAR) studies, which help in identifying the chemical moieties critical for binding affinity and selectivity towards APCDD1. These studies are instrumental in enhancing the efficacy of the inhibitors while minimizing off-target effects. The inhibitors are usually synthesized through complex organic synthesis routes, employing various chemical reactions to achieve the desired molecular architecture. This synthesis is followed by rigorous biochemical assays to confirm their inhibitory activity. The chemical class of APCDD1 inhibitors is notable for its specificity and the precision with which it can modulate the Wnt/β-catenin pathway by directly interacting with the APCDD1 protein, showcasing the intricate relationship between chemical structure and biological function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
IWR-1 inhibits Wnt signaling by stabilizing the Axin-scaffolded destruction complex, leading to the degradation of β-catenin. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV-939 selectively inhibits Wnt pathway by promoting β-catenin degradation through stabilization of Axin. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $352.00 $1270.00 | 2 | |
LGK-974 is a Porcupine inhibitor, blocking Wnt ligand secretion and thereby inhibiting Wnt signaling. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 inhibits Wnt production by blocking Porcupine, a membrane-bound O-acyltransferase. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $178.00 $367.00 | 7 | |
FH535 inhibits both Wnt/β-catenin and PPAR signaling pathways, affecting cell proliferation and differentiation. | ||||||
JW 55 | 664993-53-7 | sc-364517 sc-364517A | 10 mg 50 mg | $172.00 $726.00 | ||
JW 55 antagonizes Wnt/β-catenin signaling by promoting β-catenin's degradation and inhibiting its nuclear translocation. | ||||||
PRI-724 | 1422253-38-0 | sc-507535 | 25 mg | $255.00 | ||
PRI-724 disrupts the interaction between β-catenin and CBP, a co-activator of Wnt/β-catenin signaling. | ||||||
PNU-74654 | 113906-27-7 | sc-258020 sc-258020A | 5 mg 25 mg | $128.00 $485.00 | 7 | |
PNU-74654 inhibits Wnt signaling by disrupting the interaction between β-catenin and TCF. | ||||||